Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Colorcon
McKinsey
Merck
Moodys

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,280,468

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,280,468
Title:Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
Inventor(s): Harkin; Denis Paul (Dromore, GB), Kennedy; Richard (Belfast, GB), Keating; Katherine E. (Magherafelt, GB), McCavigan; Andrena (Derryadd Lurgan, GB), Hill; Laura A. (Lisburn, GB), Deharo; Steve (Belfast, GB), Davison; Timothy (Hillsborough, GB), Patterson; Fionnuala (Hauxton, GB), Donegan; Sinead (Belfast, GB), Jellema; Gera (Portadown, GB), Gourley; Charlie (Dumfermline, GB)
Assignee: Almac Diagnostics Limited (Craigavon, GB)
Application Number:15/116,641
Patent Claims:1. A method for diagnosing and treating a patient suffering from a subtype of cancer which is resistant to anti-angiogenic therapy, comprising: obtaining a cancer sample from the patient; measuring expression levels of a biomarker panel in the cancer sample, wherein the biomarker panel is a ten-biomarker panel comprising at least IGF2, TAP1, SHISA4, ENTPD7, CDR1, SPARC, INS, NUAK1, and MATN3; determining a cancer sample expression score for the biomarker panel based on the measured expression levels; comparing the cancer sample expression score to a threshold expression score, derived from a cohort of patients with a known status of responsiveness to an anti-angiogenic agent; and treating the patient with at least one of a platinum-based chemotherapeutic agent and a mitotic inhibitor, but not an anti-angiogenic agent if the cancer sample expression score is above or equal to the threshold expression score.

2. The method of claim 1, wherein the cancer is ovarian cancer or colorectal cancer.

3. A method for diagnosing and treating a patient suffering from a subtype of cancer which is resistant to bevacizumab, comprising: obtaining a cancer sample from the patient; measuring expression levels of a biomarker panel in the cancer sample, wherein the biomarker panel is a ten-biomarker panel comprising at least IGF2, TAP1, SHISA4, ENTPD7, CDR1, SPARC, INS, NUAK1, and MATN3; determining a cancer sample expression score for the biomarker panel based on the measured expression levels; comparing the cancer sample expression score to a threshold expression score, derived from a cohort of patients with a known status of responsiveness to an anti-angiogenic agent; and treating the patient with at least one of a platinum-based chemotherapeutic agent and a mitotic inhibitor, but not bevacizumab if the cancer sample expression score is above or equal to the threshold expression score.

4. The method of claim 3, wherein the cancer is ovarian cancer or colorectal cancer.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Express Scripts
McKesson
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.